Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines - Scorecard - MDSpire

Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines

  • By

  • Valentina G. Ferreira

  • Maria Eduarda Ehlert

  • Bruna S. Pacheco

  • Fernanda S. S. Souza

  • Isadora Tisoco

  • Lucas Damé Simões

  • Bernardo A. Iglesias

  • Claudia Ó. Pessoa

  • Fabiana K. Seixas

  • Maria Lucia Z. Dagli

  • Laurie A. Rund

  • Kyle M. Schachtschneider

  • Lawrence B. Schook

  • Tiago Veiras Collares

  • July 9, 2026

  • 0 min

Share

Clinical Scorecard: In Vitro Evaluation of Palladium(II)-Porphyrin Photosensitizers in Human and Oncopig Bladder Cancer Cell Lines

At a Glance

CategoryDetail
ConditionBladder Cancer
Key MechanismsPhotodynamic therapy (PDT) utilizing palladium(II)-porphyrins to induce reactive oxygen species (ROS) and apoptosis in cancer cells.
Target PopulationPatients with bladder cancer, including those with muscle-invasive forms.
Care SettingPreclinical research using in vitro models.

Key Highlights

  • Three palladium(II)-porphyrins showed light-dependent cytotoxicity in bladder cancer cell lines.
  • Oncopig-derived models closely mimic human bladder cancer responses.
  • PDT with palladium(II)-porphyrins demonstrated potential for localized tumor destruction.

Guideline-Based Recommendations

Diagnosis

  • Bladder cancer diagnosis should consider the high recurrence and progression rates.

Management

  • Novel therapies should be evaluated using preclinical models that replicate human disease.

Monitoring & Follow-up

  • Monitor ROS generation and apoptotic markers in response to PDT.

Risks

  • Conventional therapies may cause severe side effects and fail to ensure long-term control.

Patient & Prescribing Data

Patients with bladder cancer requiring new treatment options.

Palladium(II)-porphyrins may offer a promising alternative to conventional therapies.

Clinical Best Practices

  • Utilize Oncopig-derived models for early screening of therapeutic candidates.
  • Prioritize compounds based on mechanistic insights before in vivo studies.

Related Resources & Content

Original Source(s)

Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines

  • by Valentina G. Ferreira, Maria Eduarda Ehlert, Bruna S. Pacheco, Fernanda S. S. Souza, Isadora Tisoco, Lucas Damé Simões, Bernardo A. Iglesias, Claudia Ó. Pessoa, Fabiana K. Seixas, Maria Lucia Z. Dagli, Laurie A. Rund, Kyle M. Schachtschneider, Lawrence B. Schook, Tiago Veiras Collares

  • July 9, 2026

Related Content

Smart FL: meta-learning for federated blood marrow smear classification

Telepresence avatar use for children with cancer in schools: a study on barriers and facilitators

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer